margetuximab + retifanlimab + chemotherapy

This is a **combination regimen** comprising **margetuximab** (an Fc-engineered monoclonal antibody targeting human epidermal growth factor receptor 2, HER2), **retifanlimab** (a humanized monoclonal antibody targeting programmed cell death protein 1, PD-1), and **chemotherapy** (regimens included XELOX or mFOLFOX-6 at investigator's choice). Margetuximab is designed to enhance innate and adaptive immune responses against HER2+ cells, while retifanlimab blocks PD-1, enhancing T cell function. The combination is chiefly studied for first-line treatment of **HER2-positive, PD-L1-positive** advanced or metastatic gastroesophageal junction (GEJ) or gastric cancer. Chemotherapy serves as cytotoxic backbone, while targeted and immunotherapeutic mechanisms aim to improve efficacy over standard regimens[1][3][6].

Other names

Margenza + retifanlimab + chemotherapymargetuximab plus retifanlimab plus chemotherapy